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lactic treatment of hemophilia. Patients and caregivers completed questionnaires and 
provided verbal feedback addressing several open-ended questions, including type and 
duration of bleeds, disability, impact of treatments on lifestyle and their perceptions 
about standard utility. RESULTS: Twenty-one patients or caregivers of children with 
bleeding disorders attended. Important implications for the model were noted: a) 
Patients reported that muscle bleeds can be more painful and last longer (ie, associated 
with lower utility) than joint bleeds, which are generally considered more disabling; 
b) Patients reported that the course (utility, improvement) of a typical bleed differs by 
the type of bleed (joint vs. muscle), not necessarily by bleed severity alone; c) Although 
patients reported a loss of utility during a bleed, they gradually regained the same 
level of utility/function, hence disability was not perceived as a linear process; d) Adult 
patients reported that nowadays, unlike them, children with hemophilia receiving 
prophylactic treatment are able to play sports (eg, ice hockey), thereby having better 
quality of life, an aspect not captured by standard utility instruments; e) Although 
caregiver-administered instruments for assessing quality of life in children with hemo-
philia are available, caregivers noted concern about accurately rating their child’s 
health status based on their experience. CONCLUSIONS: Although qualitative, 
patients’ perspectives revealed in this focus group demonstrated important utility 
consequences for the economic model that are not represented in the literature.
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BACKGROUND: Observational studies, if conducted appropriately, play an impor-
tant role in the decision-making process providing invaluable information on effective-
ness, patient-reported outcomes and costs in a real-world environment. OBJECTIVES: 
A systematic review of large-scale, prospective, cohort studies with the aim of (a) 
summarising design characteristics, the interventions or aspects of the disease studied 
and the outcomes measured and (b) investigating methodological quality. METHODS: 
We included prospective, cohort studies which included at least 100 adults with 
psoriasis or psoriatic arthritis. Studies were identiﬁed through searches in electronic 
databases (Pubmed, Medline, Cochrane library, Centre for Reviews and Dissemina-
tion). Information on study characteristics were extracted and tabulated and quality 
assessment, using a checklist of 18 questions, was conducted.RESULTS: Thirty ﬁve 
papers covering 16 cohorts met the inclusion criteria. There were 10 treatment-related 
studies, only 2 of which provided a comparison between treatments, and 6 non-
treatment studies which examined a number of characteristics of the disease including 
mortality, morbidity, cost of illness and health-related quality of life. All studies 
included a clinical outcome measure and 11 included patient-reported outcomes, 
however only two studies reported information on patient utilities and two on costs. 
Quality ranged from 41% to 89%. Studies did well on a number of quality assessment 
questions including having clear objectives, documenting selection criteria, providing 
a representative sample, deﬁning interventions/characteristics under study, deﬁning 
and using appropriate outcomes, describing results clearly and using appropriate 
statistical tests. The quality assessment criteria least adhered to involved questions 
regarding sample size calculations, describing potential selection bias, deﬁning and 
adjusting for confounders and losses to follow-up, and deﬁning and describing a 
comparison group. CONCLUSIONS: The review highlights the need for well designed 
prospective observational studies on the effectiveness, patient-reported outcomes and 
economic impact of treatment regimes for patients with psoriasis and psoriatic arthritis 
in a real-world environment.
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ORGANIZATION: Agency for Health Technology Assessment in Poland (AHTAPol) 
serves as an advisory body to support the Minister of Health and relevant policy 
makers in the decision-making process in the public sector of health care in a 38 
million people country. PROBLEM OR ISSUE ADDRESSED: During 2007 in Poland, 
patients with metastatic renal cell carcinoma (mRCC), seventh-leading cause of death 
in men and in ninth-leading cause in women due to cancer, had access only to immu-
nomodulatory therapy. GOALS: Necessity of providing access to cost-effective new 
treatments in the ﬁrst line of therapy of mRCC. OUTCOMES ITEMS USED IN THE 
DECISION: Clinical efﬁcacy, safety, evidence from different levels of reliability (RCT, 
RCT interim analysis, patient registry), quality of life, cost-effectiveness/ cost-utility 
IMPLEMENTATION STRATEGY: Consultative Council (CC) of AHTAPol debated 
on the subject multiple times and given a new decision after each manufacturer’s 
submission comprised of a new HTA report updated as soon as the newest evidence 
was published RESULTS: In 2008–2009, CC debated over 3 claims for the reimburse-
ment of sunitinib and one for the reimbursement of bevacizumab in the indication: 
ﬁrst line treatment of mRCC. The ﬁrst submission on sunitinib, was based on an 
interim analysis of an international multicenter III phase randomized controlled trial 
(RCT) and 4 observational studies. The claim was rejected, on April 1, 2008, on the 
grounds of insufﬁcient data on overall survival (OS) and inacceptable level of cost-
effectiveness of app. USD 330 thousand per LYG, much higher than three-fold GDP 
recommended by WHO. The second submission, containing evidence from the ﬁrst 
submission together with ﬁnal results of the III phase trial available as conference 
presentation and abstract, was also rejected by CC on October 28, 2008. Claiming 
that a conference presentation and abstract are not sufﬁciently reliable evidence, CC 
concluded that no new evidence was presented and cost-effectiveness remained unac-
ceptably high. Meanwhile, August 6, 2008, CC rejected submission of bevacizumab 
on the grounds of unacceptably low level of submitted HTA report, especially in the 
sections comprising safety issues and economical analysis. Third and ﬁnal submission 
on sunitinib was debated on March 2, 2009. CC was presented the evidence from two 
previous submissions and a newly published data of BC Cancer Registry—a registry 
of patients with mRCC. This data on practical effectiveness showing prolongation of 
OS, rather that unreliable evidence on efﬁcacy derived from conference materials, 
persuaded CC to recommend reimbursement of sunitinib for Polish patients. After 
that crucial decision, National Health Fund created a dedicated therapeutic program 
for patients with mRCC with sunitinib as a ﬁrst line treatment. On December 12, 
2009 CC rejected second submission of bevacizumab because there was no evidence 
of its superiority over already reimbursed sunitinib. LESSONS LEARNED: Utilizing 
evidence from different levels can broaden decision maker’s perspective and justify 
coverage of sometimes expensive but socially demanded new treatments. In certain 
cases, there is a lack of evidence from the irrefutably well designed and conducted 
clinical controlled trials and thorough analysis of observational studies can give 
enough additional data to issue an informed decision. Data from large patient regis-
tries can be crucial to the decision-making process.
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ORGANIZATION: Veteran Affairs San Diego Healthcare System (VASDHS) is a 
242-bed medical facility that provides comprehensive medical, surgical, mental health, 
rehabilitation, spinal cord injury, and extended care services for over 57,000 veterans. 
VASDHS is part of the Department of Veterans Affairs which is an integrated health 
care organization that operates using a national formulary, provides outpatient and 
inpatient specialty services and uses a comprehensive electronic medical record system. 
PROBLEM OR ISSUE ADDRESSED: The absence of an accepted system for evaluat-
ing appropriate utilization of disposable medical supplies present decision makers with 
concern for how resources are managed in this category of budget expenditures. There 
is no current standard in place for technology assessments for durable medical equip-
ment (DME) requiring disposable medical supplies in a pharmacy beneﬁt management 
(PBM) plan with the potential for extensive budgetary and utilization management 
challenges to our health care system. With the introduction of CGM to the US market, 
the American Diabetes Association has recognized CGM as a useful tool for clinicians 
and patients. Local health care systems are now faced with identifying the speciﬁc 
utility of this new technology for their patient population. GOALS: (1) Develop health 
technology criteria for use for CGM sensors (2) Assess diabetes outcomes after patients 
are approved for CGM device and sensors. OUTCOMES ITEMS USED IN THE 
DECISION: Clinical efﬁcacy/effectiveness included: HbgA1c (pre-post CGM sensors 
utilization), incidence of hypoglycemia, and Emergency Department and hospital 
admissions due to hypoglycemia. IMPLEMENTATION STRATEGY: The local Phar-
macy and Therapeutics (P&T) committee approved a criterion for use (CFU) for the 
CGM sensors that required providers to measure clinical efﬁcacy and patient outcomes 
in order to facilitate the decision making process for authorization. The pharmacy 
service implemented the P&T committee CFU in conjunction with a medical staff 
reviewer from our national headquarters for approval of the DME device. RESULTS: 
Twelve out of 15 patients who received the CGM devices were evaluable at 6 months. 
All patients were on insulin (100%), most were diagnosed with type I diabetes (92%), 
83% had hypoglycemia unawareness, and there was an average reduction of 0.13% 
HbgA1c following CGM intervention. No incidences of hypoglycemic events requiring 
hospitalizations occurred following the receipt of CGM, with 67% of patients report-
ing a reduction in frequency of hypoglycemic episodes. The average time to patient 
receipt of device was 90 days (d) (SD 76 d, median 73 d) from date of provider request. 
Fiscal Year 2009 (FY2009) VASDHS Pharmacy budget impact was estimated as 
$18,480. Annualized cost for CGM device and sensors ranged from $740 to $3520 
per patient based on patients reﬁll rates in FY2009. LESSONS LEARNED: There was 
a gap in communication that was identiﬁed within the CGM device approval process. 
Final decisions by the reviewer were not communicated to the provider who initiated 
the request for the CGM device in a timely manner. This led to a delay in getting 
patients the CGM devices. Hypoglycemic events that require hospitalization is a 
preventable economic burden to the PBM and society. CGM devices showed beneﬁt 
in eliminating unnecessary hospitalizations due to hypoglycemia and reducing the 
frequency of hypoglycemic events by alerting patients of the potential danger prior to 
it evolving in to a major problem.
